Stada, a biopharmaceutical company based in Germany, recently announced that it is increasing its presence in the biosimilar sphere by becoming the majority shareholder in Bioceuticals, a venture capital-funded organization created by Stada to carry out its biosimilar programs.
Stada, a biopharmaceutical company based in Germany, recently announced that it is increasing its presence in the biosimilar sphere by becoming the majority shareholder in Bioceuticals, a venture capital-funded organization created by Stada to carry out its biosimilar programs.
In addition to the shares Stada previously held in the company, it will be acquiring another 35.48%, creating a combined total of 51.34% stake in Bioceuticals. The financial terms of the agreement have not been disclosed, and the arrangement is subject to the approval by antitrust authorities.
Bioceuticals is responsible for the production of active ingredient erythropoietin. Previously, the company issued sales licenses to third parties such as Stadapharma, a subsidiary of Stada, for the marketing of the biosimilar epoetin zeta (sold in the European Union under brand name Silapo) which treats anemia caused by chronic kidney failure and chemotherapy.
The epoetin zeta biosimilar is also sold under an agreement between Stada and Hospira, a Pfizer subsidiary, under the brand name Retacrit in various countries (the FDA approved the product this past May, though it has yet to reach the market in the United States).
In March, Claudio Albrecht, CEO of Stada, spoke out about the new direction the company was taking. “Moving ahead, we will be pursuing a 3-pillar strategy consisting of non-prescription over-the-counter products, generics, and specialty pharmaceuticals including biosimilars. The latter will focus on oncology, the central nervous system, and ophthalmology.”
In addition, Albrecht’s plan included investments of more than $115 million (€100 million) over the next 3 years in the biosimilar sector alone.
Last month, Stada entered into a collaboration agreement with Xbrane Biopharma for the development of a ranibizumab biosimilar, referencing Lucentis, which will prospectively be sold as Xlucane in the US, European, and other markets.
Currently, the European Medicine’s Agency is reviewing Stada’s pegfilgrastim biosimilar application, for which the company has entered into a licensing and marketing agreement with Gedeon Richter.
“We are pursuing the goal of a strong presence for all 3 pillars of our business model in as many countries as possible through the greater internationalization of our existing product portfolio and acquisitions,” said Albrecht.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.